Articles tagged with Cancer Patients
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
A new computational model, IRMMa, predicts personalized prognosis for newly diagnosed multiple myeloma patients based on tumor genomics and treatments. The model improves on previous prognostic tools by taking into account individualized risk and distinct subtypes of the disease.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A study found that patients with breast cancer are more likely to choose distant hospitals for surgery based on factors such as age, ethnicity, and living location. The investigation highlights the potential for healthcare inequalities to worsen if policies do not address these disparities.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
A new study found that patients treated at community cancer centers have poorer survival rates compared to those at academic medical centers. The study analyzed data from over 20,000 patients with HPV-related oropharyngeal squamous cell cancers.
Researchers at Brigham and Women's Hospital found nearly 6,000 additional US patients could benefit from immunotherapy treatment due to mismatch repair deficiency. Next-generation sequencing revealed previously missed cases, improving patient outcomes.
Researchers at NUS Yong Loo Lin School of Medicine discovered that certain breast tumour cells sacrifice their own growth to aid other cells in resisting chemotherapy, leading to higher chances of recurrence. Disrupting this cooperation could lead to more effective treatments.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A study by the University of Sydney and University of Warwick found large gaps in evidence regarding opioid medicines for cancer pain. Non-opioid medicines, including aspirin, may be as effective as opioids for background cancer pain.
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.
A study of 64 patients with MSI-H/dMMR metastatic colorectal cancer found that 88% had not experienced a recurrence two years after stopping immunotherapy. The progression-free survival rate was 98% at one year and 84% at three years post-treatment.
A phase II clinical trial found that psilocybin-assisted therapy significantly reduced depressive symptoms in adults with cancer and major depression. Participants who received the therapy experienced a decrease in depression severity scores, with 80% showing sustained responses to treatment.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Scientists have introduced a new class of protease-activity sensors using gold nanoparticles equipped with peptide DNA, which can detect multiple active proteases in parallel. The method works at room temperature and does not require complicated sample preparation or elaborate instruments.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...
A systematic review has identified 29 primary risk factors associated with long-term arm morbidities following breast cancer treatments. The main risk factors include removal of lymph nodes, high body mass index, mastectomy, radiation therapy, chemotherapy, infection, and trauma to the affected arm.
A clinical trial found that using MRI and a DCIS gene profile can guide treatment decisions for patients with low-risk ductal carcinoma in situ (DCIS). Patients who received a score lower than 39 were considered low-risk and could safely forego adjuvant radiotherapy, with similar rates of disease recurrence compared to those with high-...
Women who reduced mammography frequency three years after curative breast cancer surgery had comparable outcomes to those receiving annual screening. The Mammo-50 trial found that de-escalation did not worsen survival rates or increase recurrence, while also reducing healthcare burden and stress.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
Imetelstat, a telomerase inhibitor, successfully treated anaemia in MDS patients for up to one year, reducing the need for red blood cell transfusions. The drug offers a novel mechanism of action for patients with lower-risk MDS who do not respond to standard treatment.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...
Researchers developed a predictive model using baseline sociodemographic and financial measures to identify patients at high risk of stopping treatment with aromatase inhibitors. The model found four demographic and financial factors associated with increased non-adherence, including younger age and lower out-of-pocket costs.
Outdated medical tools cause delayed recognition and management of adverse reactions in patients of color, leading to significant distress. A more inclusive approach is urgently needed to address structural racism in radiotherapy treatment and education.
A study published at the Radiological Society of North America annual meeting found that attending regular mammograms can lower breast cancer mortality rates by up to 72%. Women who missed a scheduled mammogram had a significantly reduced survival rate, emphasizing the importance of adherence to screening schedules.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A deep learning AI model developed using mammographic images alone accurately predicted both ductal carcinoma in situ (DCIS) and invasive carcinoma, showing no bias across multiple races. The model outperformed traditional risk models in predicting breast cancer risk, providing a more accurate and equitable assessment.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
A new AI tool combines cancerous and non-cancerous cell patterns to predict breast cancer outcomes, allowing for more precise treatment plans. This could lead to reduced chemotherapy duration and intensity for some patients.
The University of Cincinnati is conducting a clinical trial to test the safety and effectiveness of lattice therapy, a method of delivering radiation that targets specific areas of tumors. The trial aims to enroll 37 adult patients and analyze the underlying biology of tumor and immune responses to lattice therapy radiation.
A novel contamination-detection method enables faster and safer T-cell therapy production, reducing the risk for patients and speeding up treatment. The method uses cutting-edge technology to identify harmful microorganisms within 24 hours.
A study of 103,000 early-stage breast cancer patients reveals a significant racial disparity in chemosensitivity and survival rates. Black patients are more likely to experience residual disease after neoadjuvant chemotherapy, leading to a higher mortality risk.
A new study found that most people with colorectal cancer in sub-Saharan Africa receive inadequate treatment, leading to significantly improved life expectancy through simple measures. The mortality rate is up to 3.5 times higher in regions studied compared to countries with medium HDI scores.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
A UCLA study found that hospitals with high patient diversity are less likely to offer core cancer services, including hospice care, chemotherapy, and robotic surgery. The lack of these resources can impact treatment quality and outcomes for patients diagnosed with cancer.
Researchers developed an AI model using epigenetic factors to predict patient outcomes across multiple cancer types. The model successfully divided patients into two groups with different survival chances, and its genes were found to have a significant overlap with cluster-defining signature genes.
Elea Abisamra's STEM writing program at Virginia Tech has been recognized by the journal Cell for its innovative approach to teaching science through storytelling. The program has already helped 95 kids publish books with over 150 tutors as editors, and plans to expand globally.
A study published in PLOS ONE found that 35% of women with breast cancer used self-discovered or peer-recommended techniques to enhance their sexual function. These techniques fell into four main domains: pain reduction, intimacy and relationship enhancement, desire and arousal enhancement, and emotional coping.
A new ASTRO clinical guideline recommends partial breast irradiation as a viable alternative to whole breast radiation for patients with early-stage invasive breast cancer or DCIS, based on evidence from large randomized trials. The guideline provides guidance on patient selection and best practices for delivering effective partial bre...
A new AI method combines satellite imaging and ecological analysis techniques to interpret large amounts of data from tumor tissue, providing insights into how cancer works. This approach aims to tailor cancer treatments to individual needs and avoid unnecessary side effects.
The Max Foundation has started treating three patients with advanced breast cancer, including a CDK4/6 inhibitor therapy, in Mozambique. This marks the first time this treatment is available in low-income countries and aims to improve outcomes for women living with advanced breast cancer.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
A study of 3.5 million patients diagnosed with cancer found a deficit in cancer treatments during the first year of the pandemic. The data showed decreases in cancer diagnoses but not changes in treatment strategies, highlighting the impact of the pandemic on cancer care.
Patients with breast cancer in conflict zones face significant barriers to treatment, including lack of standard procedures and funding for rebuilding capacity. This results in many patients being diagnosed with advanced breast cancer, often with limited palliative care options.
A Mayo Clinic study found patients with lower extremity lymphedema had twice the risk of developing skin cancer, including basal cell carcinomas and squamous cell carcinomas. Regular skin cancer screenings are crucial for these patients as early detection is critical.
A multinational study of almost one million individuals found a strong association between exposure to radiation from CT scans in young people and an increased risk of blood cancers. The study confirms that the benefits of computed tomography outweigh the risks, but emphasizes the need for strict radiological protection measures, parti...
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
A new study suggests that analyzing genetic material from nearby healthy tissue may help predict lung cancer's return after treatment. The study analyzed RNA from tumor cells and adjacent, seemingly normal lung tissue and found that the expression of genes associated with inflammation was especially useful for making predictions.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.